| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Article |
From the Institute of Pathology,*
the Department of
Surgery,
Universitäts-Frauenklinik,
University of
Basel, Basel, Switzerland; the Cancer Genetics
Branch,
National Human Genome Research
Institute, National Institutes of Health, Bethesda, Maryland;
Kreiskrankenhaus,¶
Lörrach, Germany; and
Frauenklinik,||
Rheinfelden, Germany
Advances in genomics and proteomics are dramatically increasing the need to evaluate large numbers of molecular targets for their diagnostic, predictive or prognostic value in clinical oncology. Conventional molecular pathology techniques are often tedious, time-consuming, and require a lot of tissue, thereby limiting both the number of tissues and the number of targets that can be evaluated. Here, we demonstrate the power of our recently described tissue microarray (TMA) technology in analyzing prognostic markers in a series of 553 breast carcinomas. Four independent TMAs were constructed by acquiring 0.6 mm biopsies from one central and from three peripheral regions of each of the formalin-fixed paraffin embedded tumors. Immunostaining of TMA sections and conventional "large" sections were performed for two well- established prognostic markers, estrogen receptor (ER) and progesterone receptor (PR), as well as for p53, another frequently examined protein for which the data on prognostic utility in breast cancer are less unequivocal. Compared with conventional large section analysis, a single sample from each tumor identified about 95% of the information for ER, 75 to 81% for PR, and 70 to 74% for p53. However, all 12 TMA analyses (three antibodies on four different arrays) yielded as significant or more significant associations with tumor-specific survival than large section analyses (p < 0.0015 for each of the 12 comparisons). A single sample from each tumor was sufficient to identify associations between molecular alterations and clinical outcome. It is concluded that, contrary to expectations, tissue heterogeneity did not negatively influence the predictive power of the TMA results. TMA technology will be of substantial value in rapidly translating genomic and proteomics information to clinical applications.
This article has been cited by other articles:
 |
|
 |
|
  M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Moeder, J. M. Giltnane, M. Harigopal, A. Molinaro, A. Robinson, K. Gelmon, D. Huntsman, R. L. Camp, and D. L. Rimm Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray Based Assessment of Outcome J. Clin. Oncol., December 1, 2007; 25(34): 5418 - 5425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Melck, H. Masoudi, O. L. Griffith, A. Rajput, G. Wilkins, S. Bugis, S. J. M. Jones, and S. M. Wiseman Cell Cycle Regulators Show Diagnostic and Prognostic Utility for Differentiated Thyroid Cancer. Ann. Surg. Oncol., December 1, 2007; 14(12): 3403 - 3411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Ullenhag, A. Mukherjee, N. F.S. Watson, A. H. Al-Attar, J. H. Scholefield, and L. G. Durrant Overexpression of FLIPL Is an Independent Marker of Poor Prognosis in Colorectal Cancer Patients Clin. Cancer Res., September 1, 2007; 13(17): 5070 - 5075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hu, X. He, K. A. Baggerly, K. R. Coombes, B. T.J. Hennessy, and G. B. Mills Non-parametric quantification of protein lysate arrays Bioinformatics, August 1, 2007; 23(15): 1986 - 1994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Duncan, P. Rolland, S. Deen, I. V. Scott, D. T.Y. Liu, I. Spendlove, and L. G. Durrant Loss of IFN{gamma} Receptor Is an Independent Prognostic Factor in Ovarian Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4139 - 4145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Lee, S.-B. Cho, H. E. Lee, M. A Kim, J. H. Kim, D. J. Park, J. H. Kim, H.-K. Yang, B. L. Lee, and W. H. Kim Protein Expression Profiling and Molecular Classification of Gastric Cancer by the Tissue Array Method Clin. Cancer Res., July 15, 2007; 13(14): 4154 - 4163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Lugli, I Zlobec, K Baker, P Minoo, L Tornillo, L Terracciano, and J R Jass Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status J. Clin. Pathol., May 1, 2007; 60(5): 534 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rolland, Z. Madjd, L. Durrant, I. O Ellis, R. Layfield, and I. Spendlove The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease Endocr. Relat. Cancer, March 1, 2007; 14(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Lam, A. J. Pantuck, A. S. Belldegrun, and R. A. Figlin Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials Clin. Cancer Res., January 15, 2007; 13(2): 703s - 708s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zimpfer, S. Schonberg, A. Lugli, C. Agostinelli, S. A Pileri, P. Went, and S. Dirnhofer Construction and validation of a bone marrow tissue microarray J. Clin. Pathol., January 1, 2007; 60(1): 57 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bertucci, D. Birnbaum, and A. Goncalves Proteomics of Breast Cancer: Principles and Potential Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Su, M. J. Shrubsole, R. M. Ness, Q. Cai, N. Kataoka, K. Washington, and W. Zheng Immunohistochemical Expressions of Ki-67, Cyclin D1, {beta}-Catenin, Cyclooxygenase-2, and Epidermal Growth Factor Receptor in Human Colorectal Adenoma: A Validation Study of Tissue Microarrays. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1719 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dolled-Filhart, A. McCabe, J. Giltnane, M. Cregger, R. L. Camp, and D. L. Rimm Quantitative In situ Analysis of {beta}-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome. Cancer Res., May 15, 2006; 66(10): 5487 - 5494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Callagy, P. D. Pharoah, S. E. Pinder, F. D. Hsu, T. O. Nielsen, J. Ragaz, I. O. Ellis, D. Huntsman, and C. Caldas Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index Clin. Cancer Res., April 15, 2006; 12(8): 2468 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Linke, T. M. Bremer, C. D. Herold, G. Sauter, and C. Diamond A Multimarker Model to Predict Outcome in Tamoxifen-Treated Breast Cancer Patients Clin. Cancer Res., February 15, 2006; 12(4): 1175 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Jubb and K Hillan Expression of HIF-1{alpha} in human tumours J. Clin. Pathol., December 1, 2005; 58(12): 1344 - 1344. [Full Text] [PDF]
|
|
|
|
|
|
B. Willipinski-Stapelfeldt, S. Riethdorf, V. Assmann, U. Woelfle, T. Rau, G. Sauter, J. Heukeshoven, and K. Pantel Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells Clin. Cancer Res., November 15, 2005; 11(22): 8006 - 8014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Nambiar, S. R. Boutin, R. Raja, and D. W. Rosenberg Global Gene Expression Profiling: A Complement to Conventional Histopathologic Analysis of Neoplasia Vet. Pathol., November 1, 2005; 42(6): 735 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Harigopal, A. J. Berger, R. L. Camp, D. L. Rimm, and H. M. Kluger Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer Clin. Cancer Res., June 1, 2005; 11(11): 4083 - 4089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Chang, B. C. Yoo, S.-B. Lim, S.-Y. Jeong, W. H. Kim, and J.-G. Park Metabotropic Glutamate Receptor 4 Expression in Colorectal Carcinoma and Its Prognostic Significance Clin. Cancer Res., May 1, 2005; 11(9): 3288 - 3295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Handerson, R. Camp, M. Harigopal, D. Rimm, and J. Pawelek {beta}1,6-Branched Oligosaccharides Are Increased in Lymph Node Metastases and Predict Poor Outcome in Breast Carcinoma Clin. Cancer Res., April 15, 2005; 11(8): 2969 - 2973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Sheehan, V. S. Calvert, E. W. Kay, Y. Lu, D. Fishman, V. Espina, J. Aquino, R. Speer, R. Araujo, G. B. Mills, et al. Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma Mol. Cell. Proteomics, April 1, 2005; 4(4): 346 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Alvaro, M. Lejeune, M. T. Salvado, R. Bosch, J. F. Garcia, J. Jaen, A. H. Banham, G. Roncador, C. Montalban, and M. A. Piris Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells Clin. Cancer Res., February 15, 2005; 11(4): 1467 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jacquemier, C. Ginestier, J. Rougemont, V.-J. Bardou, E. Charafe-Jauffret, J. Geneix, J. Adelaide, A. Koki, G. Houvenaeghel, J. Hassoun, et al. Protein Expression Profiling Identifies Subclasses of Breast Cancer and Predicts Prognosis Cancer Res., February 1, 2005; 65(3): 767 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Al-Kuraya, P. Schraml, J. Torhorst, C. Tapia, B. Zaharieva, H. Novotny, H. Spichtin, R. Maurer, M. Mirlacher, O. Kochli, et al. Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer Cancer Res., December 1, 2004; 64(23): 8534 - 8540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Berger, R. L. Camp, K. A. DiVito, H. M. Kluger, R. Halaban, and D. L. Rimm Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome Cancer Res., December 1, 2004; 64(23): 8767 - 8772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Th. Went, S. Dirnhofer, M. Bundi, M. Mirlacher, P. Schraml, S. Mangialaio, S. Dimitrijevic, J. Kononen, A. Lugli, R. Simon, et al. Prevalence of KIT Expression in Human Tumors J. Clin. Oncol., November 15, 2004; 22(22): 4514 - 4522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Camp, M. Dolled-Filhart, and D. L. Rimm X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization Clin. Cancer Res., November 1, 2004; 10(21): 7252 - 7259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Makretsov, D. G. Huntsman, T. O. Nielsen, E. Yorida, M. Peacock, M. C. U. Cheang, S. E. Dunn, M. Hayes, M. van de Rijn, C. Bajdik, et al. Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6143 - 6151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Hirsch, M. Varella-Garcia, P. A. Bunn Jr, M. V. Di Maria, R. Veve, R. M. Bremnes, A. E. Baron, C. Zeng, and W. A. Franklin In Reply: J. Clin. Oncol., September 1, 2004; 22(17): 3646 - 3648. [Full Text]
|
|
|
|
 |
|
 R. B. West, C. L. Corless, X. Chen, B. P. Rubin, S. Subramanian, K. Montgomery, S. Zhu, C. A. Ball, T. O. Nielsen, R. Patel, et al. The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status Am. J. Pathol., July 1, 2004; 165(1): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-P. Lim, C. Y. Wong, L. L. Ooi, B. J. Druker, and R. J. Epstein Selective Tyrosine Hyperphosphorylation of Cytoskeletal and Stress Proteins in Primary Human Breast Cancers: Implications for Adjuvant Use of Kinase-Inhibitory Drugs Clin. Cancer Res., June 15, 2004; 10(12): 3980 - 3987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Tornillo, H Moch, P-A Diener, A Lugli, and G Singer CDX-2 immunostaining in primary and secondary ovarian carcinomas J. Clin. Pathol., June 1, 2004; 57(6): 641 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bao, A. Kimzey, G. Sauter, J. M. Sowadski, K. P. Lu, and D.-G. Wang Prevalent Overexpression of Prolyl Isomerase Pin1 in Human Cancers Am. J. Pathol., May 1, 2004; 164(5): 1727 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Woelfle, G. Sauter, S. Santjer, R. Brakenhoff, and K. Pantel Down-Regulated Expression of Cytokeratin 18 Promotes Progression of Human Breast Cancer Clin. Cancer Res., April 15, 2004; 10(8): 2670 - 2674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Diaz, R. Gupta, N. Kidwai, N. Sneige, and E. L. Wiley The Use of TMA for Interlaboratory Validation of FISH Testing for Detection of HER2 Gene Amplification in Breast Cancer J. Histochem. Cytochem., April 1, 2004; 52(4): 501 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-I. Saez, A.-J. Saez, M.-J. Artiga, A. Perez-Rosado, F.-I. Camacho, A. Diez, J.-F. Garcia, M. Fraga, R. Bosch, S.-M. Rodriguez-Pinilla, et al. Building an Outcome Predictor Model for Diffuse Large B-Cell Lymphoma Am. J. Pathol., February 1, 2004; 164(2): 613 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O. Nielsen, H. N. Andrews, M. Cheang, J. E. Kucab, F. D. Hsu, J. Ragaz, C. B. Gilks, N. Makretsov, C. D. Bajdik, C. Brookes, et al. Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival: Potential for Intervention with 17-Allylamino Geldanamycin Cancer Res., January 1, 2004; 64(1): 286 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Simon, S. Panussis, R. Maurer, H. Spichtin, K. Glatz, C. Tapia, M. Mirlacher, A. Rufle, J. Torhorst, and G. Sauter KIT (CD117)-Positive Breast Cancers Are Infrequent and Lack KIT Gene Mutations Clin. Cancer Res., January 1, 2004; 10(1): 178 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Davis Making Mechanistic Connections between Cell Signaling Pathways and Pathological Endpoints Toxicol Pathol, January 1, 2004; 32(1_suppl): 131 - 135. [Abstract] [PDF]
|
|
|
|
|
|
P. Schraml, A. Hergovitz, F. Hatz, M. B. Amin, S. D. Lim, W. Krek, M. J. Mihatsch, and H. Moch Relevance of Nuclear and Cytoplasmic von Hippel Lindau Protein Expression for Renal Carcinoma Progression Am. J. Pathol., September 1, 2003; 163(3): 1013 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Palacios, E. Honrado, A. Osorio, A. Cazorla, D. Sarrio, A. Barroso, S. Rodriguez, J. C. Cigudosa, O. Diez, C. Alonso, et al. Immunohistochemical Characteristics Defined by Tissue Microarray of Hereditary Breast Cancer Not Attributable to BRCA1 or BRCA2 Mutations: Differences from Breast Carcinomas Arising in BRCA1 and BRCA2 Mutation Carriers Clin. Cancer Res., September 1, 2003; 9(10): 3606 - 3614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Packeisen, E Korsching, H Herbst, W Boecker, and H Buerger Demystified ... Tissue microarray technology Mol. Pathol., August 1, 2003; 56(4): 198 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Petricoin and L. A. Liotta Clinical Applications of Proteomics J. Nutr., July 1, 2003; 133(7): 2476S - 2484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Camp, M. Dolled-Filhart, B. L. King, and D. L. Rimm Quantitative Analysis of Breast Cancer Tissue Microarrays Shows That Both High and Normal Levels of HER2 Expression Are Associated with Poor Outcome Cancer Res., April 1, 2003; 63(7): 1445 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Kang, M. Dolled-Filhart, I. T. Ocal, B. Singh, C.-Y. Lin, R. B. Dickson, D. L. Rimm, and R. L. Camp Tissue Microarray Analysis of Hepatocyte Growth Factor/Met Pathway Components Reveals a Role for Met, Matriptase, and Hepatocyte Growth Factor Activator Inhibitor 1 in the Progression of Node-negative Breast Cancer Cancer Res., March 1, 2003; 63(5): 1101 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dolled-Filhart, R. L. Camp, D. P. Kowalski, B. L. Smith, and D. L. Rimm Tissue Microarray Analysis of Signal Transducers and Activators of Transcription 3 (Stat3) and Phospho-Stat3 (Tyr705) in Node-negative Breast Cancer Shows Nuclear Localization Is Associated with a Better Prognosis Clin. Cancer Res., February 1, 2003; 9(2): 594 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Garcia, F. I. Camacho, M. Morente, M. Fraga, C. Montalban, T. A. C. Bellas, A. Castano, A. Diez, T. Flores, C. Martin, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays Blood, January 15, 2003; 101(2): 681 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van de Rijn, C. M. Perou, R. Tibshirani, P. Haas, O. Kallioniemi, J. Kononen, J. Torhorst, G. Sauter, M. Zuber, O. R. Kochli, et al. Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome Am. J. Pathol., December 1, 2002; 161(6): 1991 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Liu, W. Prapong, Y. Natkunam, A. Alizadeh, K. Montgomery, C. B. Gilks, and M. van de Rijn Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays Am. J. Pathol., November 1, 2002; 161(5): 1557 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Otis, P. A. Krebs, A. Albuquerque, M. M. Quezado, X. S. Juan, M. E. Sobel, and M. J. Merino Loss of Heterozygosity of p53, BRCA1, VHL, and Estrogen Receptor Genes in Breast Carcinoma: Correlation with Related Protein Products and Morphologic Features International Journal of Surgical Pathology, October 1, 2002; 10(4): 237 - 245. [Abstract] [PDF]
|
|
|
|
|
|
C. Ginestier, E. Charafe-Jauffret, F. Bertucci, F. Eisinger, J. Geneix, D. Bechlian, N. Conte, J. Adelaide, Y. Toiron, C. Nguyen, et al. Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers Am. J. Pathol., October 1, 2002; 161(4): 1223 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P.H. Pritzker Cancer Biomarkers: Easier Said Than Done Clin. Chem., August 1, 2002; 48(8): 1147 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Sauter and M Mirlacher Tissue microarrays for predictive molecular pathology J. Clin. Pathol., August 1, 2002; 55(8): 575 - 576. [Full Text] [PDF]
|
|
|
|
|
|
Vet. Pathol., March 1, 2002; 39(2): 292 - 292. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
